ArticleCureus2021
Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Early potential safety signals for gliptins and gliflozins using real-world pharmacy data compared to spontaneous reporting.PloS one · 2026Observational
- Role of sodium-glucose cotransporter 2 inhibitors in liver diseases.World journal of experimental medicine · 2025Review
- Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.Journal of clinical medicine · 2024Review
- Telangiectasia Macularis Eruptiva Perstans in a 55-Year-Old Female With Type 2 Diabetes Mellitus.Cureus · 2024Article
- Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview ofits Chemistry, Pharmacology, and Toxicology.Current diabetes reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) have revolutionized the treatment of type 2 diabetes mellitus during the last decade. It has not only proven to be very effective for glycemic control but also has adjunctive effects in the management of heart failure, hypertension, and diabetic nephropathy, and even contributes to weight loss. Another benefit is the apparent lack of major side effects, particularly hypoglycemia, apart from euglycemic diabetic ketoacidosis. The most well-known side effects are genital mycotic infections and urinary tract infections (UTI). Although pruritus is less well known, we highlight in this case study this side effect as notable albeit uncommon so as to sensitize clinicians to its possibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.